When Cerba Research launched a facility in New York 20 years ago, it established itself as a major clinical diagnostics and clinical laboratory services supplier in the United States. Cerba Research has enlarged this facility — now our U.S. Immuno-Oncology Center of Excellence — to better serve our global client base, allowing us to provide even more comprehensive, integrated central lab services, specialty lab and biomarker solutions, and diagnostic services globally.
Cerba Research U.S. relocated into a 30% larger building in July, with no interruption in operations, offering the lab 35,000 square feet more than before. To make the most of the available space, the US team brought in more cutting-edge technology, enlarged its testing, sample handling, and logistics departments, and welcomed more scientific and operational specialists.
It’s a new space with a lot of light and a lot of color,” says Chief Operating Officer Nele Langenaken, who founded Cerba Research U.S. in 1999. “Overall, it provides a clean, inviting, positive environment, which helps improve efficiency and motivation among staff, as well as helps us attract and retain top scientific talent.”
Cerba Research USA will continue to work closely with Northwell Health, the region’s largest laboratory. Cerba Research U.S. can handle rapid turnaround and large-volume requests thanks to its support, which includes more than 75 pathologists and a facility that handles more than 30,000 tests every day.
Cerba Research U.S. is a first choice for precision medicine clinical trials due to its professional scientists and cutting-edge equipment.
The industry is moving from quantity to quality and from routine to specialized,” says Cerba Research Chief Executive Officer Mario Papillon. “Nele created an ideal environment for customized assay development and validation for R&D projects.”
The following are the most recent Cerba Research U.S. updates:
Triple the flow cytometry capacity. As a result, Cerba Research U.S. was able to more than treble its complicated flow cytometry capacity as a result of the expansion. Automated flow cytometers and full spectrum devices with up to 40 colors have been added to the equipment.
We not only expanded our capabilities, we also optimized the process and created space for a new level of excellence in flow cytometry,” says Langenaken.
Quadruple the PBMC capacity. Immunology, infectious disease, and oncology research all rely on peripheral blood mononuclear cells (PBMCs). Cerba Research U.S. improved its PBMC and cell isolation capacity as a result of the expansion, allowing it to handle up to four times more sample volume than the prior location.
Increased kit production. In comparison to the same period last year, Cerba Research U.S. increased kit manufacturing by 40% in 2021. It will be able to increase output even further with the larger facilities.
Increased sample reception and storage. Cerba Research’s expanded U.S. facility receives 8,000 to 10,000 tubes every day. Over the next three years, we expect that figure to rise by 20 to 25%. Additional storage capacity covers ambient to -20° and -80° C temperatures, as well as liquid nitrogen, all of which are centrally monitored by a temperature monitoring system.
A more powerful group. With a larger facility comes a larger team. The US team now has enough scientists and operational specialists to handle even the most difficult initiatives.
The increased flow cytometry, PBMC, and IHC capabilities give the US CoE an even bigger worldwide footprint to serve immuno-oncology clinical studies. CerbACT Asia, Cerba Research’s other immuno-oncology Center of Excellence, is a purpose-built facility in Taiwan that offers cutting-edge technologies in FCM, histopathology, IHC, and NGS sequencing.
We have a substantial team of flow cytometry scientists in the U.S., all with high international profiles,” says Papillon. “Combined with the clinical expertise of Northwell Health, our capabilities in North America are remarkable.”
Cerba Research is part of a global network with seven offices and access to over 400 labs on five continents, so you can be confident that no matter how global your trial is, Cerba Research has the expertise and capacity to assist it from early research to commercialization.
Cerba Research, a strategic diagnostic solutions provider, aids medication development by integrating patient data and scientific expertise to improve R&D and commercialization throughout the globe. Through our global network of speciality laboratories, we provide early phase research, clinical development through central laboratories and diagnostic testing, assay and biomarker creation and validation. To transform the image of clinical development and advance healthcare, we collaborate with government agencies, non-profit groups, and pharmaceutical and biotech companies.
Cerba Research is a division of Cerba HealthCare, a renowned medical diagnostics company.